Propranolol: Nursing Drug Guide, Bronchospasm Risk & Hold Rules
Nonselective beta blocker for hypertension, angina, migraine, tremor, and other indications: because it blocks beta-1 and beta-2 receptors, the bedside priority is screening for asthma and reactive airways before the first dose—bronchospasm, bradycardia, hypotension, and heart block can develop or worsen, insulin-treated patients may not feel typical hypoglycemia warnings, and abrupt withdrawal in coronary artery disease can trigger severe angina, myocardial infarction, or ventricular arrhythmias.
Propranolol blocks beta-1 and beta-2 adrenergic receptors, slowing heart rate and reducing contractility while preventing bronchodilation. The worst realistic failures are bronchospasm in asthma or reactive airways (a labeled contraindication), symptomatic bradycardia, hypotension, and AV block—especially with digoxin or verapamil on the MAR—and masked hypoglycemia symptoms in diabetes. In coronary artery disease, abrupt discontinuation can precipitate severe angina, myocardial infarction, or ventricular arrhythmias per labeling. Measure apical pulse for a full minute and blood pressure before each dose, assess lungs for wheeze, hold when out of range, and coordinate prescriber-guided tapering when therapy stops.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Screen asthma and reactive airway history before every new order. Count apical pulse for a full minute, check blood pressure, and listen for wheeze; hold when below limits or if bronchospasm develops. Teach diabetes patients that tremor and fast heartbeat may not warn of low glucose. Never stop abruptly in angina or post-MI patients—taper per prescriber guidance.
Most common brand names
Inderal and generic propranolol hydrochloride tablets are the familiar oral products. InnoPran XL is an extended-release once-daily formulation. Hemangeol is an oral solution for infantile hemangioma per specialized labeling. IV propranolol is given per prescriber order in selected acute settings.
Confirm strength, immediate-release versus extended-release schedule, and that the patient is not receiving a second beta blocker from another prescriber or home medication list.
| Product | Formulation | Nursing verification |
|---|---|---|
| Inderal / propranolol tablets | Immediate-release oral; multiple strengths | Usually divided doses (e.g., BID–QID); food increases bioavailability ~50% |
| InnoPran XL | Extended-release once daily | Swallow whole—do not crush or chew without pharmacy approval |
| Hemangeol | Oral solution for infantile hemangioma | Specialized pediatric protocol—verify indication and weight-based dose |
| IV propranolol | Per order in monitored settings | Verify concentration, rate, and hemodynamic monitoring per protocol |
On a small screen, swipe or scroll sideways to see the full table.
Why we give it — Indications
Propranolol is a nonselective beta-adrenergic blocker used when heart rate, myocardial oxygen demand, or adrenergic symptoms must be reduced across cardiovascular, neurologic, and other indications per current orders.
| Use | Detail |
|---|---|
| Hypertension | Lowers blood pressure; usual initial 40 mg twice daily; maintenance often 120–240 mg/day; max up to 640 mg/day per labeling |
| Angina pectoris | Long-term treatment; typical range 80–320 mg/day divided |
| Atrial fibrillation rate control | Often 10–30 mg three to four times daily per labeling—verify rhythm versus rate-control goals |
| Post–myocardial infarction | 180–240 mg/day divided when hemodynamically stable per order and institution pathway |
| Migraine prophylaxis | Initial 80 mg/day divided; effective range often 160–240 mg/day |
| Essential tremor | Initial 40 mg twice daily; optimum often 120 mg/day |
| Heart failure adjunct | Used cautiously in selected patients—watch for decompensation during titration |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Propranolol competitively blocks beta-1 and beta-2 adrenergic receptors, decreasing heart rate and contractility while also blocking beta-2–mediated bronchodilation. It is lipophilic and crosses the blood–brain barrier, contributing to CNS effects such as fatigue, sleep disturbance, and vivid dreams. Reduced myocardial oxygen demand helps control angina; lower cardiac output contributes to antihypertensive action.
| Physiologic effect | Clinical result | Nursing implication |
|---|---|---|
| Beta-1 blockade | Bradycardia, reduced contractility | Full-minute apical pulse before every dose |
| Beta-2 blockade | Bronchospasm in reactive airways | Contraindicated in bronchial asthma—assess lungs before first dose |
| ↓ Renin release | Lower BP over days | Expect gradual antihypertensive effect during titration |
| AV nodal effects | Heart block risk with nodal drugs | Review digoxin and verapamil orders; hold for new block |
| Masks adrenergic hypoglycemia cues | Blunted tachycardia/tremor during low glucose | Scheduled glucose checks in diabetes; teach alternate warning signs |
| Lipophilic / CNS penetration | Fatigue, sleep changes, depression reported | Assess mental status and functional impact after dose changes |
On a small screen, swipe or scroll sideways to see the full table.
Dosing overview
Dosing depends on indication, formulation (immediate-release versus extended-release), hepatic function, and response. Verify each order against current prescribing information—do not assume once-daily ER dosing for standard immediate-release tablets.
| Scenario | Typical approach (labeling summary) | Nursing note |
|---|---|---|
| Atrial fibrillation rate control | 10–30 mg TID–QID | Verify rhythm goals; monitor pulse and blood pressure each dose |
| Post-MI maintenance | 180–240 mg/day divided | Never discontinue abruptly in ischemic heart disease |
| Hepatic impairment | Start lower; titrate slowly | Propranolol is hepatically metabolized—levels may rise |
| Food effect | Bioavailability increases ~50% with food | Encourage consistent timing relative to meals |
| Extended-release (InnoPran XL) | Once daily per order | Swallow whole; do not crush without pharmacy approval |
| IV use | Per prescriber order in monitored settings | Follow institution IV beta-blocker protocol |
On a small screen, swipe or scroll sideways to see the full table.
Missed dose: Not specified in the reviewed prescribing information for a single missed dose. Do not double doses. Contact prescriber or pharmacist if multiple doses are missed, especially in coronary artery disease, because abrupt interruption increases ischemic risk.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Onset (antihypertensive) | Not specified as a single numeric value | Expect gradual blood pressure lowering during titration |
| Peak effect (oral) | About 1–4 hours after dosing per labeling | Assess vitals across the shift—not only at one fixed time |
| Half-life | About 3–6 hours (oral) | Shorter than many once-daily agents—missed doses and abrupt stops still carry CAD withdrawal risk |
| Food | Increases bioavailability ~50% | Teach consistent meal timing relative to doses |
| Metabolism / excretion | Hepatic metabolism; renal excretion of metabolites | Lower starting dose in hepatic impairment; trend basic metabolic panel when clinically indicated |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Apical pulse for a full minute and blood pressure (supine and standing when orthostasis is a concern)
- Respiratory assessment: history of asthma, COPD, or reactive airways; auscultate for wheezing
- Medication reconciliation for other beta blockers, digoxin, verapamil, and rescue albuterol availability
- Blood glucose trends in type 2 diabetes or insulin-treated patients
- Electrocardiogram (ECG) or rhythm strip if history of heart block, syncope, or new palpitations
Contraindications (labeling)
- Cardiogenic shock
- Sinus bradycardia and greater than first-degree heart block
- Bronchial asthma
- Known hypersensitivity to propranolol
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Digoxin | Additive AV nodal depression; bradycardia risk | Monitor pulse and rhythm; hold per parameters |
| Verapamil / diltiazem | Increased bradycardia and heart block risk | Verify orders; trend vitals; escalate symptomatic hypotension |
| Insulin / oral hypoglycemics | Masks hypoglycemia symptoms | Teach glucose monitoring; do not rely on tachycardia alone |
| Epinephrine (anaphylaxis / overdose) | Unopposed alpha effects possible with nonselective blockade | Document beta-blocker use; follow protocol—epinephrine not first-line for propranolol overdose bradycardia |
On a small screen, swipe or scroll sideways to see the full table.
When propranolol is discontinued in patients with angina or after myocardial infarction, taper gradually per prescriber guidance and monitor for increased angina, arrhythmias, or blood pressure rebound.
Administration
Route: Oral tablets or solution; IV propranolol per prescriber order in monitored settings.
- Immediate-release: usually with or immediately after meals for consistent absorption—food increases bioavailability ~50%
- Extended-release (InnoPran XL): once daily; swallow whole unless pharmacy approves modification
- Ensure rescue bronchodilator (e.g., albuterol) is available if reactive airways history exists and prescriber continues therapy
- Bedside identification: read full label for strength and immediate-release versus extended-release before every pass
| Administration step | Action |
|---|---|
| Before dose | Apical pulse (60 seconds), blood pressure, lung sounds, compare to hold parameters |
| During pass | Right patient, drug, dose, route, time; question new orders in active asthma |
| After dose | Reassess for wheeze, dizziness, or glucose symptoms in diabetes |
| Discharge | Teach taper if discontinuing; warn against stopping when BP improves |
On a small screen, swipe or scroll sideways to see the full table.
Expected therapeutic response
- Gradual reduction in resting heart rate and blood pressure toward prescriber targets
- Decreased frequency or severity of angina episodes when used for coronary artery disease
- Reduced migraine frequency or tremor amplitude when used for those indications
- Patient reports improved exercise tolerance without presyncope—if dizziness or fatigue worsen, reassess dose and hold parameters
Red flags — Stop and act
Bronchospasm, bradycardia, and abrupt withdrawal in ischemic heart disease are equally dangerous with nonselective blockade.
- New or worsening wheeze, shortness of breath, or declining SpO2 after a dose—hold and escalate respiratory pathway
- Heart rate below prescriber hold limit, new second- or third-degree AV block, or pauses on monitor
- Symptomatic hypotension, syncope, or cold clammy extremities after dose
- Rest angina, crushing chest pain, or diaphoresis after missed doses or self-discontinuation
- Confusion, sweating, or hunger with normal-appearing pulse in diabetes—suspect masked hypoglycemia
- Signs of heart failure decompensation during titration in reduced ejection fraction
Adverse effects
| Adverse effect | Frequency / notes | Nursing response |
|---|---|---|
| Bradycardia | Common; dose-related | Hold dose, notify prescriber, obtain rhythm strip; prepare for pacing pathway if symptomatic |
| Hypotension / dizziness | Common early in therapy or after dose increase | Assist with position changes; hold per parameters; monitor orthostatics |
| Fatigue, depression, sleep disturbance | Reported in beta-blocker class | Assess functional impact; notify prescriber if limits ADLs |
| Bronchospasm | Expected with nonselective beta-2 blockade | Hold drug; bronchodilator therapy per prescriber; document allergy/intolerance |
| Masked hypoglycemia symptoms | Class effect in diabetes | Emphasize glucose checks; educate on sweating and confusion as alternate cues |
| Peripheral coldness / Raynaud symptoms | Class effect | Assess extremity perfusion; notify prescriber if painful or cyanotic |
| Sleep disturbance / vivid dreams | Central nervous system effect reported with beta blockers | Assess timing of dose; notify prescriber if distressing or persistent |
| Heart failure decompensation | May occur during HF up-titration | Notify prescriber; adjust diuretics; hold or reduce dose per order |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Propranolol overdose may cause severe bradycardia, hypotension, cardiogenic shock, AV block, bronchospasm, and impaired consciousness per labeling.
Management per labeling
- Treat in intensive care with continuous monitoring
- Glucagon 50–150 mcg/kg IV bolus, then 1–5 mg/hour infusion
- Bradycardia: atropine; isoproterenol if refractory per protocol
- Epinephrine is NOT indicated—unopposed alpha stimulation may worsen hypotension
- Bronchospasm: bronchodilators per protocol
- Hemodialysis is not significantly effective per labeling
Contact local poison control or medical toxicology services for overdose guidance per facility protocol and local emergency guidance.
Look-alike / sound-alike and error prevention
- Propranolol vs prednisolone—sound-alike risk; read full generic name on MAR and pharmacy label
- Inderal vs InnoPran XL—immediate-release divided doses are not interchangeable with once-daily ER without prescriber order
- Propranolol vs propranolol / atenolol—all end in “-olol”; nonselective propranolol carries higher bronchospasm risk
- Multiple beta blockers—duplicate therapy from inpatient and home lists
- Strength errors—12.5, 25, 50, 100, 200 mg tablets exist across products; HF titration starts low
- Crushing ER tablets—dose dumping risk if succinate is crushed for enteral administration without pharmacy approval
- Abrupt stop—patient may confuse hold for stop; document taper orders clearly
High-risk populations
| Population | Considerations |
|---|---|
| Coronary artery disease / post-MI | Never discontinue abruptly; taper gradually with monitoring per prescriber guidance; rebound angina and MI reported |
| Older adults | Start 25 mg daily; higher risk of bradycardia and hypotension; fall risk with dizziness |
| Hepatic impairment | Initiate at low doses; titrate gradually—blood levels may increase substantially per labeling |
| Diabetes mellitus | Masks hypoglycemia tachycardia; monitor glucose closely |
| Reactive airway disease | Avoid in bronchial asthma; bronchospasm is a labeled contraindication |
| Pregnancy / lactation | Consult LactMed and MotherToBaby references; fetal growth restriction reported with beta blockers—balance maternal benefit vs risk with prescriber |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Apical pulse (full minute), blood pressure, and rhythm before each dose and when symptoms change
- Orthostatic vital signs after dose increases or in fall-risk patients
- Signs of worsening heart failure during succinate up-titration (weight, edema, crackles, dyspnea)
- Blood glucose trends in diabetes; angina frequency and exertional symptoms in CAD
Document
- Heart rate, blood pressure, and whether dose was held with prescriber notification
- Taper plan when discontinuing; patient education on not stopping abruptly
- Any bronchospasm, syncope, or angina after missed doses
| Parameter | Typical nursing frequency | Action threshold (verify local protocol) |
|---|---|---|
| Apical pulse | Before each dose; when symptoms change | Hold and notify if below prescriber minimum (often <60/min in adults) |
| Blood pressure | Before each dose; orthostatics after dose changes | Hold for symptomatic hypotension or SBP below protocol limit |
| Rhythm | When pulse irregular or patient reports palpitations | Obtain ECG or rhythm strip; hold for new AV block |
| Lung sounds | Before first dose and when respiratory symptoms change | Hold for wheeze; question orders in active asthma |
| Blood pressure measurement | Before each dose; orthostatics after dose changes | Accurate BP underpins every hold decision |
| Blood glucose | Per diabetes plan when on insulin or sulfonylureas | Teach alternate hypoglycemia cues when beta blocker masks tachycardia |
| Angina symptoms | Each shift in CAD; after missed doses | Escalate rest angina or increasing frequency—possible withdrawal or undertreatment |
On a small screen, swipe or scroll sideways to see the full table.
Patient teaching
- Take at the same time daily; do not double doses if one is missed—call the clinic for guidance
- Never stop suddenly if you have heart disease or angina; prescriber will taper the dose
- Check pulse before taking if instructed; report heart rate below your prescriber limit, fainting, or new wheezing
- Rise slowly from sitting or lying down to reduce dizziness
- If you have diabetes, monitor blood glucose as directed—this medicine can hide shaking and fast heartbeat during low sugar
- Inform all clinicians and dentists that you take a beta blocker before procedures requiring epinephrine or certain anesthetics
| Teach-back topic | Patient should be able to say |
|---|---|
| Pulse check | How to count pulse for one minute and when to call if too slow |
| Missed doses | Do not double; call clinic if several doses missed |
| Stopping therapy | Prescriber must taper—never stop suddenly if heart disease |
| Diabetes | Sweating or confusion may still occur; check glucose as directed |
| When to seek care | Fainting, severe dizziness, chest pain, new wheezing |
On a small screen, swipe or scroll sideways to see the full table.
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Apical pulse below prescriber or protocol minimum (commonly <60 beats/min in adults—verify institutional parameters)
- Systolic blood pressure below hold threshold or symptomatic hypotension
- New second- or third-degree AV block, sick sinus syndrome, or symptomatic bradycardia on monitor
- Active bronchospasm or severe reactive airway exacerbation
- Patient self-discontinued or multiple doses missed in CAD—do not restart full dose without prescriber/pharmacy plan
- Active asthma or new wheeze after dose—labeled contraindication; notify prescriber before giving
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
| Common institutional hold example | Nursing action |
|---|---|
| Apical pulse <60/min | Hold dose; notify prescriber; recheck in 30–60 minutes per protocol |
| SBP <100 mmHg or symptomatic low BP | Hold; orthostatic assessment; notify prescriber |
| New heart block or irregular pulse | Hold; obtain rhythm strip; urgent notification |
| Active wheeze / bronchospasm | Hold; treat respiratory symptoms; notify prescriber |
On a small screen, swipe or scroll sideways to see the full table.
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Pulse check | Apical count full 60 seconds—radial pulse may be irregular or weak with block |
| Timing | Tartrate often BID; succinate once daily—teach the patient their specific schedule |
| Perioperative | Continue or hold per anesthesia/prescriber plan—abrupt withdrawal risky in CAD |
| Formulation | Never crush InnoPran XL; verify IV propranolol only when IV order is active |
| Commonly missed | Second beta blocker on home list; wrong salt on MAR; patient stops drug when BP looks normal |
| Ask pharmacy when | Hepatic dose adjustment, salt substitution, nodal drug interactions, or taper after MI/angina |
On a small screen, swipe or scroll sideways to see the full table.
Clinical practice integration and workflow
Propranolol safety hinges on asthma screening, vital signs before every dose, lung assessment for wheeze, glucose teaching in diabetes, and disciplined tapering at discontinuation.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, time—and right apical pulse and blood pressure
- Compare heart rate to hold parameters on the MAR and nursing protocol
- Screen for duplicate beta-blocker therapy on MAR and home med list
- Screen asthma history and rescue bronchodilator availability before first dose
2. High-alert and safety badge
Not an ISMP high-alert medication, but bradycardia and withdrawal ischemia require the same vital-sign disciplineTreat pre-dose pulse and blood pressure checks as non-negotiable even when the drug is not on your facility high-alert list.
3. Clinical workflow: hold and question rules
- If pulse or blood pressure is below threshold, hold and notify before giving—do not administer and document later
- If asthma is on the problem list but propranolol is newly ordered, stop and clarify with prescriber/pharmacy before the first dose
- If the patient skipped several doses, clarify restart vs taper with pharmacy—especially post-MI or angina
- Before surgery, confirm perioperative beta-blocker plan with anesthesia and cardiology
4. Critical teach-back questions
- “What should you do if your pulse is too slow before your pill?” (Hold and call prescriber/clinic per instructions—do not take the dose.)
- “Can you stop this medicine when your blood pressure looks good?” (No—prescriber must taper; sudden stop can cause chest pain or heart attack in heart disease.)
5. Care coordination
Pharmacist: Renal dosing, interaction review with digoxin and calcium channel blockers, taper schedules
Prescriber / cardiology: Symptomatic bradycardia, heart block, failed angina control, or perioperative beta-blocker decisions
🧠 Quick mental checklist
- Asthma or reactive airways on chart—should this drug be given?
- Apical pulse for full minute and BP before this dose?
- Any wheeze or new shortness of breath?
- Diabetes patient—glucose checked and hypoglycemia cues taught?
- Any nodal drugs (digoxin, verapamil) increasing block risk?
- If stopping therapy, is there a taper—not abrupt discontinuation?
Propranolol NCLEX practice questions
Practice NCLEX-style clinical judgment practice for propranolol with a tabbed case (MAR, labs, vitals, nursing notes) focused on asthma, wheezing, bradycardia, and masked hypoglycemia—then priority action, select-all-that-apply cues, deterioration trends, matrix urgency sorting, withdrawal judgment, and overdose cloze—recognise bronchospasm and hold cues → analyse interactions → prioritise escalation → act → evaluate outcomes after each intervention.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Propranolol 40 mg PO BID — new order, first hospital dose due 0800
- Albuterol MDI 2 puffs q4h PRN wheeze — used twice overnight
- Metformin 1000 mg PO BID with meals
- Digoxin 0.125 mg PO daily — given 0700
- Fasting glucose 62 mg/dL at 0600 (was 108 yesterday); patient ate dinner
- Creatinine 0.9 mg/dL; potassium 4.0 mEq/L
- Pharmacy note: propranolol may mask hypoglycemia adrenergic symptoms
- Apical pulse 54/min regular; BP 118/70 supine
- SpO2 94% on room air; mild expiratory wheeze bilateral bases
- Hold parameters: give if apical pulse ≥60 and SBP ≥100; hold for active wheeze
- History: hypertension, type 2 diabetes, childhood asthma with ED visit last year
- 0730: Patient asks why a “heart pill” was ordered when lungs “act up in cold weather”
- Home list reviewed: no beta blocker at home; states he “feels shaky” when sugar is low but pulse stays slow
Answer key & rationale
Frequently asked questions
Common nursing questions about propranolol focus on asthma contraindications, bronchospasm holds, masked hypoglycemia teaching, safe tapering, and overdose management when epinephrine is not first-line.
Why is propranolol contraindicated in asthma?
Propranolol blocks beta-2 receptors in bronchial smooth muscle, which can precipitate bronchospasm. Bronchial asthma is a labeled contraindication. Screen respiratory history, auscultate lungs, and hold for wheeze before every dose.
When should a nurse hold propranolol?
Hold for symptomatic bradycardia or hypotension, active wheeze or bronchospasm, heart block greater than first degree, cardiogenic shock, or plans to stop abruptly without taper in angina or recent myocardial infarction.
How does propranolol affect hypoglycemia warning signs?
It can mask tachycardia and tremor during low glucose. Teach patients with diabetes to monitor blood sugar on schedule and recognize sweating, hunger, and confusion as alternate cues.
Can propranolol be stopped suddenly?
No. Abrupt discontinuation in coronary artery disease can worsen angina or precipitate myocardial infarction. Taper gradually over 1 to 2 weeks with monitoring per prescriber guidance.
What adverse effects matter most with propranolol?
Bronchospasm in reactive airways, bradycardia, hypotension, heart block, masked hypoglycemia, fatigue, and CNS effects such as sleep disturbance are the highest-impact bedside concerns with nonselective blockade.
References
-
U.S. National Library of Medicine. PROPRANOLOL HYDROCHLORIDE tablet — Full prescribing information (Mylan). DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8cbac6dc-ef1d-6662-e053-2995a90af13f
-
Drugs and Lactation Database (LactMed). Propranolol. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/n/lactmed/LM228/
-
U.S. National Library of Medicine. Propranolol — Clinical pharmacology summary. StatPearls.https://www.ncbi.nlm.nih.gov/books/NBK501142/
-
American Heart Association. Types of blood pressure medications — Beta blockers.https://www.heart.org/en/health-topics/high-blood-pressure/changes-you-can-make-to-manage-high-blood-pressure/types-of-blood-pressure-medications
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.
.